Company news

PTC Therapeutics, Inc. news in 2026

PTC Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

November 3, 2026

PTC Therapeutics to Participate in Upcoming Investor Conferences

November 2, 2026

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 30, 2026

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

October 29, 2026

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

October 15, 2026

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 21, 2026

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

August 24, 2026

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

August 12, 2026

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

July 30, 2026

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

July 16, 2026

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

June 15, 2026

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

June 15, 2026

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026

Ardena Strengthens Executive Team to Drive its Next Phase of Growth

May 4, 2026

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

April 28, 2026

PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

April 21, 2026

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

March 24, 2026

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

February 19, 2026

PTC Therapeutics Provides Regulatory Update on Translarna™

February 12, 2026

PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

February 5, 2026

PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

January 12, 2026

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 8, 2026

Calls in 2026

Decks in 2026